A Multicenter, Phase 1/2 Study of Ramucirumab Plus Nivolumab as Second-line Therapy in Participants With Gastric or GEJ Cancer

Trial Profile

A Multicenter, Phase 1/2 Study of Ramucirumab Plus Nivolumab as Second-line Therapy in Participants With Gastric or GEJ Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Sep 2017

At a glance

  • Drugs Nivolumab (Primary) ; Ramucirumab (Primary)
  • Indications Adenocarcinoma; Gastric cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 18 Sep 2017 Planned End Date changed from 31 Dec 2018 to 1 Jan 2019.
    • 18 Sep 2017 Planned primary completion date changed from 1 Jun 2019 to 1 Jan 2018.
    • 12 Sep 2017 Trial design of the study presented at the 42nd European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top